The fast, safe solution for vascular thrombosis.

The EkoSonic™ Endovascular System:

- Quality clinical outcomes
- Predictable results
- Minimised bleeding risk
- Efficient procedures



Pulmonary Embolism

- Reduces RV/LV ratio by more than 25% on average[7]
- Reduces PA pressures by 28% (at 48 hours)[7]
- 76% less thrombolytic drug dosage than standard treatment[7]
- Minimised risk of bleeding[6]

Deep Vein Thrombosis

- 50% of DVT patients have PE[9]
- Removes thrombus more completely compared to CDT[10]
- Reduces post-thrombotic syndrome[11]

Arterial Occlusion

- Lower 30-day amputation rate[2]
- Lower bleeding rates when compared to CDT[2]
- Higher complete dissolution rate of thrombus[2]

The EKOS™ effect (in green) changes the standard of care for pulmonary embolism and dissolves the thrombus more completely, even in difficult-to-reach areas for deep vein thrombosis and peripheral arterial occlusion.

EKOS™

References

1. Lin, P., et al., "Comparison of Percutaneous Ultrasound-Accelerated Thrombolysis versus Catheter-Directed Thrombolysis in Patients with Acute Massive Pulmonary Embolism." *Vascular*, Vol. 17, Suppl. 3, 2009, S137–S147.

2. Litzendorf, M., et al., "Ultrasound-Accelerated Thrombolysis Is Superior to Catheter-Directed Thrombolysis for the Treatment of Acute Limb Ischemia." *Journal of Vascular Surgery*, Jun 2011; 53(Suppl S), p106S-107S.

3. De Vries, J., et al., "RCT Comparing Standard Thrombolysis with US Accelerated Thrombolysis: The DUET Study and Beyond." Charing Cross International Symposium, London, UK, April 2014.

4. Parikh, S., et al., "Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience." *Journal of Vascular and Interventional Radiology*, Vol. 19, Issue 4, April 2008, 521–528.

5. Lin, P., et al., "Catheter-Directed Thrombectomy and Thrombolysis for Symptomatic Lower-Extremity Deep Vein Thrombosis: Review of Current Interventional Treatment Strategies." *Perspectives in Vascular Surgery and Endovascular Therapy*, 2010, 22(3): 152–163.

6. Kucher, N., et al., "Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism." *Circulation*, Vol. 129, No. 4, 2014, 479–486.

7. Piazza, G., et al., "A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism (Seattle II)." American College of Cardiology 63rd Annual Scientific Session, Washington, D.C., March 30, 2014.

8. Francis, C.W., et al., "Ultrasound Accelerates Transport of Recombinant Tissue Plasminogen Activator into Clots." *Ultrasound in Medicine and Biology*, 21.3, 1995, 419–424.

9. Kahn, Sr. Shrier I. Julien, J.A., et al., "Determinants and Time Course of the Post-thrombotic Syndrome After Acute Deep Venous Thrombosis." *Annals of Internal Medicine*, 149, 2008, 698–707.

10. Mewissen, et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry." *Radiology*, 1999 Apr; 211(1): 39-49.

11. Engelberger, R., et al., "Fixed, Low-Dose Ultrasound-Assisted Catheter-Directed Thrombolysis Followed by Routine Stenting of Risidual Stenosis for Acute Ilio-Femoral Deep-Vein Thrombosis." *Journal of Thrombosis and Haemostasis*, 2014, 111.6.

12. Soltani, A., et al., "Absence of Biological Damage from Prolonged Exposure to Intravascular Ultrasound: A Swine Model." *Ultrasonics*, 46, 2007, 60–67.

13.Braaten, J.V., et al., "Ultrasound Reversibly Disaggregates Fibrin Fibers." *Journal of Thrombosis and Haemostasis*, 78, 1997, 1063–8.

14. Wissgott C., et al., "Treatment of Critical Limb Ischemia Using Ultrasound-Enhanced Thrombolysis (PARES TRIAL): Final Results." *Journal of Endovascular Therapy*, 14(4), 2007, 438–443.

15. Schrijver, A.M., et al., "Dutch Randomized Trial Comparing Standard Catheter-Directed Thrombolysis Versus Ultrasound-Accelerated Thrombolysis for Arterial Thromboembolic Infrainguinal Disease (DUET)" *Journal of Endovascular Therapy* 2015; 22(1):87-95.

About EKOS™

EKOS Corporation, a BTG International group company, pioneered the development and clinical application of ultrasound infusion technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005.

Today, interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS™ EkoSonic™ Endovascular System to provide faster, safer and more complete dissolution of thrombus. To find out more about the EKOS™ EkoSonic™ Endovascular System, visit www.ekoscorp.com.

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, advanced emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges.

To learn more about BTG, please visit: www.btgplc.com.

INDICATIONS FOR USE: The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥25 mmHg) or echocardiographic evaluation. Contraindications: Not designed for peripheral vasculature dilation purposes. This system is contraindicated when, in the medical judgment of the physician, such a procedure may compromise that patient's condition. Such conditions include but are not limited to: • Tortuous vascular anatomy compromising safe introduction of endovascular equipment • Conditons associated with increased risk of bleeding. See device instructions for use for complete prescribing information http://ekoscorp.com/international_enter.htm#Resources

The EkoSonic™ Endovascular System

106cm Working Length: Includes one 5.4 F infusion catheter (106cm long, 0.035 inch guidewire compatible) and one ultrasonic core matched to infusion length.	
500-55106	6cm Treatment Zone
500-55112	12cm Treatment Zone
500-55118	18cm Treatment Zone
500-55124	24cm Treatment Zone
500-55130	30cm Treatment Zone
500-55140	40cm Treatment Zone
500-55150	50cm Treatment Zone
135cm Working Length: Includes one 5.4 F infusion catheter (135cm long, 0.035 inch guidewire compatible) and one ultrasonic core matched to infusion length.	
500-56112	12cm Treatment Zone
500-56130	30cm Treatment Zone
500-56140	40cm Treatment Zone
500-56150	50cm Treatment Zone
600-20000	EkoSonic™ Control Unit with CIC and CIC Clip.
All EKOS™ products are latex free.	

Contact us:

Address: Lakeview, Riverside Way, Watchmoor Park, Camberley, Surrey GU15 3YL UK
Email: customerservice@ekoscorp.com
Website: www.ekoscorp.com
Online Learning Center: www.ekoscorp.com/learningcenter.htm

Imagine where we can go.

BTG

EKOS™



EKOS™ Acoustic Pulse Thrombolysis™ Treatment

Imagine where we can go.

BTG

Quickly & safely dissolve thrombus with the EKOS™ System.

Treat smarter. Achieve more.™

Since its beginning, EKOS™ has had one goal: develop life-enhancing and lifesaving endovascular treatments for vascular thrombosis. EKOS™ is committed to developing device-based therapies that improve patient outcomes, lower risks and improve treatment predictability.

The Acoustic Pulse Difference

EKOS™ Acoustic Pulse Thrombolysis™ treatment is a minimally invasive system for dissolving thrombus. The ultrasonic core generates a localised acoustic field which greatly accelerates lytic dispersion by driving the drug deeper into the clot and unwinding the fibrin to expose plasminogen receptor sites.

Acoustic Pulse Thrombolysis™ Treatment:

- Speeds time-to-dissolution
- Increases thrombus removal and clinical improvement compared to either standard Catheter Directed Therapy (CDT) or thrombectomy[1,5]
- Lowers the risk of bleeding and other complications[1,4]

More Effective Drug Delivery:

- Reduces dosage requirements by as much as 68% compared to standard CDT[6]
- Requires up to 4x less drug dosage than systemic delivery[6,7]

Superior Thrombus Clearance[2,4]:

- 48% greater drug absorption within 1 hour[8]
- 84% greater drug absorption within 2 hours[8]

The Thrombosis Barrier



Tightly wound fibrin prevents lytic from reaching receptor sites.

With Acoustic Pulse



Ultrasonic energy thins fibrin and exposes receptor sites.

With Acoustic Pulse + Lytic



More drug reaches entire thrombus, accelerating absorption.

The EKOS™ System's targeted ultrasound waves accelerate thrombus dissolution by unwinding the fibrin matrix.

The fast, safe solution for vascular thrombosis.

The EkoSonic™ Endovascular System:

- **Quality clinical outcomes**
- **Predictable results**
- **Minimised bleeding risk**
- **Efficient procedures**



Pulmonary Embolism



RV/LV Ratio: 1.73
RV Diameter: 65.5mm
LV Diameter: 37.9mm



RV/LV Ratio: 0.98
RV Diameter: 60.4mm
LV Diameter: 61.5mm



Pre-procedural angiography



Completion angiography

Arterial Occlusion

Deep Vein Thrombosis



Femoral vein with thrombus

Thrombus resolved

Lower patient risk. Higher procedure predictability.

The EkoSonic™ Endovascular System includes an ultrasonic core within an infusion catheter, and control unit.

Targeting the Thrombus, Safely

With EKOS™ Acoustic Pulse Thrombolysis™ treatment most of the drug remains in the thrombus and you can typically use less lytic. It dissolves the thrombus without damaging vessels, valves or walls.[4,12] There is no mechanical disruption resulting in distal embolisation.[13]

The EKOS™ System's safety and efficacy is supported by Level 1 and Level 2 data.[6,7,14,15]

Reduced Procedure Time[2,4]

EKOS™ requires significantly shorter treatment times, typically only 33–50% of standard CDT. Unlike more complex surgical solutions,[1-5] EKOS™ is an efficient, three-step process:

1) Insert the EKOS™ 5.4 F infusion catheter through the thrombus.

2) Insert the ultrasonic core until it locks in place.

3) Activate the lytic infusion and acoustic pulse.

Treatment zones range from 6cm to 50cm with radiopaque marker bands at each end of the treatment zone to enhance visualisation. At-a-glance operating status, alarms and treatment times are easy to read from a distance.